Castleman's disease presenting in the lungs: A report of two cases
- Authors:
- Published online on: June 10, 2015 https://doi.org/10.3892/ol.2015.3354
- Pages: 1041-1043
Abstract
Introduction
Castleman's disease (CD) is an uncommon lymphoproliferative disorder that was initially described by Dr Castleman in 1954 (1). An important pathological feature of CD is hyperplasia of lymphoid follicles, blood vessels and plasma cells (PCs). In addition, CD is one of the common causes of non-neoplastic lymphadenopathy (2,3). The majority (70%) of CD cases have been described in the chest; however, a number of cases have also been described in the abdomen, pelvis, skeletal muscle, head and neck (3,4). Extra-lymphatic sites of involvement may include the lungs, pancreas and parotid gland (3), although the lungs are a rare site in which CD may occur. The present study described two unusual cases presenting CD of the lungs and evaluated the imaging features, highlighting the clinical features of CD in the lungs. Thus, the current study may facilitate the diagnosis, differential diagnosis and treatment of patients with CD.
Case report
Case 1
The study was approved by the Ethics Committee of Tongji University (Shanghai, China). Written informed consent was obtained from the patient. A 39-year-old female presented to Shanghai Pulmonary Hospital (Shanghai, China) in May 2013, with a mass in the lower lobes of the right lung that had been identified 2 months before. Computed tomography (CT) imaging clarified the presence of a high-density mass in the right lower lung. Compressed bronchiostenosis was identified in the outer and posterior basal segments during bronchoscopy and a lung biopsy revealed lymphocytes in the tissues. Therefore, the patient received anti-inflammatory treatment (cefuroxime, 0.75 g, 3 times/day) for 2 months; however, no evident change was observed in the lesion.
Physical examination identified no enlargement in superficial lymph nodes. Breath sounds were moderately rough and no dry or wet rales were noted. Results of routine laboratory tests and biochemical analysis of blood samples were within the normal ranges. Furthermore, rheumatoid, allergy, lung function and sputum examinations were normal. However, a conventional chest CT scan revealed a homogenous soft-tissue mass in the lower lobes of the right lung, multiple nodules in the two lungs and enlarged lymph nodes in the hilum and mediastinum (Fig. 1). No cysts or necrosis were identified, and latex agglutination and galactomannan tests were negative.
Open lung biopsy was performed and a 3.5×3.0×4.5-cm3 mass was identified in the lower lobes of the right lung. In addition, numerous 0.3-cm nodes were distributed in the upper and lower lobes of both lungs. Histopathological examination identified lymphoid hyperplasia with numerous PCs and few blood vessels were present in the interfollicular areas of the lymph nodes (Fig. 3A). Subsequent histopathological examinations were used to determine that the patient had features of hyaline-vascular (HV)- and PC-type CD. The mass was excised. No evidence of recurrence was observed during the 6-months follow-up in November 2013.
Case 2
A 40-year-old male presented to the Shanghai Pulmonary Hospital on 2 February 2013, with the symptoms of coughing and shortness of breath. A physical examination revealed numerous hard, mobile lymph nodes in the neck and supraclavicular fossa. Breath sounds were moderately rough and no dry or wet rales were noted. Biochemical analysis of blood samples identified a globulin concentration of 85 g/l (normal range, 20–40 g/l). An abdominal ultrasound identified hepatosplenomegaly and enlarged retroperitoneal lymph nodes. In addition, a contrast-enhanced CT scan revealed multiple nodules in the two lungs and enlarged lymph nodes in the hilum and mediastinum (Fig. 2). The mass was markedly and homogeneously enhanced relative to the muscles. No cysts or necrosis were identified. The patient underwent a lymph node biopsy to determine a definitive diagnosis. Pathological examination of the biopsy revealed lymphoid hyperplasia with numerous PCs in the interfollicular areas. Thus, a final histological diagnosis of PC-type multicentric CD was determined (Fig. 3B). Steroids were administered as the initial treatment strategy (prednisone, 40 mg/day). Subsequently, the sizes of the lymph nodes in the neck, supraclavicular fossa, hilum and mediastinum reduced following 2 weeks of treatment; however, no evident changes were identified in the lung mass. CHOP chemotherapy (cyclophosphamide, hydroxydaunorubicin, Oncovin and prednisone) with Mabthera was proposed as a follow-up treatment in February 2014. However, the patient refused further treatment.
Discussion
CD is a rare disease characterized by hyperplasia of the lymphoid follicles (5). The current study reported 2 cases of CD localized in the lungs. Analysis of the 2 cases indicated that a diagnosis of CD should be considered when a mass is identified in the lungs. The findings of the present study may facilitate the diagnosis, differential diagnosis and treatment of patients with CD.
CD has two clinical subtypes: Multicentric and unicentric (localized) (6). The unicentric variant of CD is the most common type and is localized to a single lymph node chain or area (5). In adults, 90% of localized CD cases are HV-type and predominantly occur in young adults (3). The thorax (mediastinum) is the most common site of localized CD; however, a number of cases have been described in other locations, such as the abdomen and neck (3,4,7,8). The multicentric variants of CD are less common, accounting for only 10–20% of cases and commonly occurring in an older age population (3). Disseminated lymphadenopathies with systemic illness, such as fever, weight loss and abnormal laboratory results, are the common clinical features of multicentric CD. Furthermore, it is associated with POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes) (3). CD may also be classified into HV-type, PC-type and mixed-type CD, according to its histological features (6). HV-type is characterized by hyperplasia and vascular proliferation in the interfollicular region, while PC-type is characterized by polyclonal PCs within the interfollicular zone (9). In the current study, case 1 suffered from mixed-type CD and case 2 presented PC-type CD. A previous study has demonstrated that the HV type was present in 75–90% of CD cases, the PC type in 10–25% of cases and the mixed type in 1–4% of cases (10). Multicentric CD is predominantly of PC type (2), which is consistent with the histological features of case 2 of the present study.
Radiological examinations, such as CT scans, can provide important information regarding CD tumors, including tumor site, characteristics and association with other tissues (3). The imaging features of CD are associated with its histological type, with previous reports demonstrating that different enhancement patterns of HV- and PC-type CT (4,11). Homogenous high enhancement is typically observed in HV-type CD due to the abundance of blood vessels. By contrast, PC-type CD typically exhibits absent or mild homogenous enhancement. However, a number of previous studies have described increased vascularity of PC-type CD on contrast-enhanced CT images (4,11). In the 2 cases in the present study, suffering from PC-type CD, homogenous enhancement was observed, which is consistent with previous studies (4,11).
The majority of localized CD cases can be cured by resection of the involved lymph nodes (3) and surgery has been proposed as the gold standard for the treatment of unicentric CD (12). For multicentric and aggressive CD, steroid treatment and/or systemic chemotherapy are required (3). However, for multicentric CD, surgical resection is rarely possible due to disseminated lymphadenopathy. Thus, a standard treatment course has yet to be established for patients with multicentric CD. In such cases, systemic therapy with steroids alone or in combination with other agents, including methotrexate or antiproliferative agents, is typically administered. In addition, it has been demonstrated that the prognosis of PC-type CD is worse compared with that of HV-type CD (3). Steroids were used in the present study in case 2, and the size of the lymph nodes were also reduced. However, no obvious changes were observed in the mass in lungs, which indicated that combined therapy with chemotherapy drugs are required.
In conclusion, CD is a rare lesion that is frequently misdiagnosed as lymphoma, thymoma, sarcoidosis or metastatic tumor, since non-specific symptoms or imaging findings are observed. The findings of the current study indicate that a diagnosis of CD should be considered for certain patients with masses in the lungs, particularly when accompanied by enlarged lymph nodes at distinct sites.
Acknowledgements
The present study was funded by the National Natural Science Foundation of China (grant no. 30971323), the Shanghai Municipal Science and Technology Commission (grant no. 09411951500) and the Shanghai Health Bureau (grant no. 2010006).
References
Castleman B and Towne VW: Case records of the Massachusetts General Hospital; weekly clinicopathological exercises; founded by Richard C. Cabot. N Engl J Med. 251:396–400. 1954.PubMed/NCBI | |
Cronin DM and Warnke RA: Castleman disease: an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 16:236–246. 2009. View Article : Google Scholar : PubMed/NCBI | |
Bonekamp D, Horton KM, Hruban RH and Fishman EK: Castleman disease: The great mimic. Radiographics. 31:1793–1807. 2011. View Article : Google Scholar : PubMed/NCBI | |
Zhou LP, Zhang B, Peng WJ, Yang WT, Guan YB and Zhou KR: Imaging findings of Castleman disease of the abdomen and pelvis. Abdom Imaging. 33:482–488. 2008. View Article : Google Scholar : PubMed/NCBI | |
Guo H, Shen Y, Wang WL, et al: Castleman disease mimicked pancreatic carcinoma: Report of two cases. World J Surg Oncol. 10:1542012. View Article : Google Scholar : PubMed/NCBI | |
Newlon JL, Couch M and Brennan J: Castleman's disease: Three case reports and a review of the literature. Ear Nose Throat J. 86:414–418. 2007.PubMed/NCBI | |
Puram SV, Hasserjian RP, Faquin WC, Lin HW and Rocco JW: Castleman disease presenting in the neck: Report of a case and review of the literature. Am J Otolaryngol. 34:239–244. 2013. View Article : Google Scholar : PubMed/NCBI | |
Macedo JE, Abreu I, Marques M, Henrique R and Araújo A: A clinical case of Castleman's disease. J Thorac Oncol. 2:259–260. 2007. View Article : Google Scholar : PubMed/NCBI | |
Lu ZH and Wu M: Localized Castleman disease of plasma cell type in the abdomen. Chin Med J (Engl). 124:2789–2791. 2011.PubMed/NCBI | |
Parker MS: Multicentric hyaline-vascular Castleman's disease. Clin Radiol. 62:707–710. 2007. View Article : Google Scholar : PubMed/NCBI | |
Kim TJ, Han JK, Kim YH, Kim TK and Choi BI: Castleman disease of the abdomen: Imaging spectrum and clinicopathologic correlations. J Comput Assist Tomogr. 25:207–214. 2001. View Article : Google Scholar : PubMed/NCBI | |
Talat N, Belgaumkar AP and Schulte KM: Surgery in Castleman's disease: A systematic review of 404 published cases. Ann Surg. 255:677–684. 2012. View Article : Google Scholar : PubMed/NCBI |